HBV Mutation Detail Information

Virus Mutation HBV Mutation A1762T


Basic Characteristics of Mutations
Mutation Site A1762T
Mutation Site Sentence [Analysis the relationship of HBV BCP A1762T/G1764A double mutation with HBV related acute on chronic liver failure].
Mutation Level Nucleotide level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region BCP
Standardized Encoding Gene
Genotype/Subtype -
Viral Reference -
Functional Impact and Mechanisms
Disease Acute-On-Chronic Liver Failure    
Immune -
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location -
Literature Information
PMID 21186523
Title [Analysis the relationship of HBV BCP A1762T/G1764A double mutation with HBV related acute on chronic liver failure]
Author Yan T,Li K,Su HB,Liu XY,Zang H,Wang HF
Journal Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
Journal Info 2010 Jun;24(3):190-2
Abstract OBJECTIVE: To analysis the relationship between HBV BCP A1762T/G1764A double mutation with acute on chronic liver failure (ACLF). METHODS: HBV BCP A1762T/G1764A double mutation was detected in 166 HBV chronic infection patients by nested PCR and direct DNA sequencing. The mutation rate was compared among the patients with different disease course. RESULTS: Among 166 patients, 45 patients, 45 patients, 49 patients and 27 patients were diagnosed as chronic hepatitis B (CHB), liver cirrhosis (LC), ACLF and hepatocellular carcinoma (HCC), respectively. A1762T/G1764A double mutation rate was 40.0% (18/45), 84.4% (38/45), 73.5% (36/49) and 92.6% (25/27) respectively in different groups. However, A1762T/G1764A double mutation rate has no difference between ACLF based on CHB and LC (P = 0.502) and between patients with HBeAg positive and negative (P = 0.735). HBV DNA level (log) of patients with A1762T/G1764A double mutation was 5.68 +/- 1.36, lower than but having no significant statistic difference compared to patients without the double mutation (6.14 +/- 1.81, P = 0.075). CONCLUSION: A1762T/G1764A double mutation has a close relationship with the progress of HBV-infection diseases, but is not specific to patients with ACLF. And patients with BCP double mutation have similar HBV DNA levels and HBeAg status with patients without the double mutation.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.